Home » Stocks » UBX

Unity Biotechnology, Inc. (UBX)

Stock Price: $4.26 USD -0.15 (-3.40%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 233.68M
Revenue (ttm) n/a
Net Income (ttm) -81.56M
Shares Out 54.17M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.26
Previous Close $4.41
Change ($) -0.15
Change (%) -3.40%
Day's Open 4.42
Day's Range 4.22 - 4.61
Day's Volume 438,963
52-Week Range 2.72 - 15.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity

2 days ago - GlobeNewsWire

UBX1325's selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ag...

2 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agin...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ag...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of agi...

2 months ago - GlobeNewsWire

Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ch...

4 months ago - PRNewsWire

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Other stocks mentioned: AUPH
4 months ago - GuruFocus

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of agi...

4 months ago - GlobeNewsWire

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board

4 months ago - GlobeNewsWire

Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on Augu...

5 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging,...

6 months ago - GlobeNewsWire

SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing disease...

7 months ago - GlobeNewsWire

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

7 months ago - GlobeNewsWire

SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing dise...

8 months ago - GlobeNewsWire

SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing disea...

8 months ago - GlobeNewsWire

Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.

8 months ago - Zacks Investment Research

Shares of Unity Biotechnology Inc (NASDAQ: UBX), which went public in mid-2018, were moving notably lower Monday following an adverse clinical readout.

8 months ago - Benzinga

The development-stage biopharma announced disappointing results from a clinical trial.

8 months ago - The Motley Fool

Unity Biotechnology Inc. (NASDAQ: UBX) stock was absolutely crushed on Monday after the company announced results from its midstage study in patients with moderate-to-severe painful osteoarthritis (OA) ...

8 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, haltin...

8 months ago - GlobeNewsWire

SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing disease...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting ...

9 months ago - GlobeNewsWire

SAN FRANCISCO, July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing d...

9 months ago - GlobeNewsWire

SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing d...

9 months ago - GlobeNewsWire

Lynne Sullivan appointed interim chief financial officer Lynne Sullivan appointed interim chief financial officer

10 months ago - GlobeNewsWire

– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 –

10 months ago - GlobeNewsWire

SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing disea...

11 months ago - GlobeNewsWire

Unity Biotechnology, Inc. (UBX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

11 months ago - Zacks Investment Research

Unity Biotechnology: A Speculative Play For 2H 2020

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Unity Biotechnology

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Unity Biotechnology.

1 year ago - Zacks Investment Research

– Topline 12- and 24-week results expected in 2H 2020 – – Topline 12- and 24-week results expected in 2H 2020 –

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. today announced that Anirvan Ghosh, Ph.D., has officially joined the company as Chief Executive Officer. As pr...

1 year ago - GlobeNewsWire

– Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan  –

1 year ago - GlobeNewsWire

– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment –

1 year ago - GlobeNewsWire

SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...

1 year ago - GlobeNewsWire

SAN FRANCISCO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing d...

1 year ago - GlobeNewsWire

SAN FRANCISCO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversin...

1 year ago - GlobeNewsWire

SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...

1 year ago - GlobeNewsWire

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

1 year ago - The Motley Fool

The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.

1 year ago - The Motley Fool

This biotech company is trying to stop or reverse age-related diseases

YouTube video

Keith Leonard, chairman and CEO of Unity Biotechnology, said that his company's mission is to extend the human "healthspan," the period in someone's life that is unburdened by disease or pain.

2 years ago - CNBC Television

About UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related ey... [Read more...]

Industry
Biotechnology
IPO Date
May 3, 2018
CEO
Anirvan Ghosh
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
UBX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for UBX stock is "Hold." The 12-month stock price forecast is 6.00, which is an increase of 40.85% from the latest price.

Price Target
$6.00
(40.85% upside)
Analyst Consensus: Hold